Sir,

Enterobacteriaceae producing metallo-β-lactamases (MBLs), and particularly VIM-type MBLs, have frequently been implicated in hospital outbreaks across Europe,^[@DKT314C1]^*bla*~VIM~ genes having been linked to Tn*402* derivatives, epidemic plasmids (IncN, IncI1, IncHI2) and occasionally with particular Enterobacteriaceae clones.^[@DKT314C1]^ VIM enzymes have been classified in three clusters (VIM-1, VIM-2 and VIM-7) according to their amino acid sequences (<http://www.lahey.org/studies>), VIM-1 and VIM-2 being the most widespread variants.^[@DKT314C5]^ In this study, we report the molecular epidemiology and the antibiotic susceptibility profiles of *Klebsiella pneumoniae* clinical isolates producing VIM-34, a novel VIM-1 variant identified in Portugal.

In October 2011 and October 2012, two *K. pneumoniae* isolates (strains K43 and K47, respectively) showing reduced susceptibility to carbapenems (MICs 0.38--1.0 mg/L) were recovered from urine samples of hospitalized patients in a general hospital in northern Portugal (Hospital Pedro Hispano). They are the only carbapenemase-producing Enterobacteriaceae isolates identified in this hospital since the beginning of 2011, when reference protocols for carbapenemase detection were adopted.

Antimicrobial susceptibility tests were performed using the Etest for β-lactams and disc diffusion for all other antimicrobial agents. These showed that all isolates were resistant to diverse cephalosporins, aztreonam, β-lactam/β-lactamase inhibitor combinations (Table [1](#DKT314TB1){ref-type="table"}), nalidixic acid, ciprofloxacin, chloramphenicol, gentamicin, kanamycin, netilmicin, streptomycin, tobramycin and sulphonamides, but susceptible to trimethoprim and amikacin (<http://www.eucast.org/)>.^[@DKT314C6]^ Standard disc diffusion phenotypic tests using different β-lactams and β-lactamase inhibitors (cefotaxime, ceftazidime, imipenem; 0.2 mM EDTA, clavulanic acid),^[@DKT314C6]^ isoelectric focusing, PCR and sequencing^[@DKT314C7]^ demonstrated the production of VIM-34 (pI = 5.4) (GenBank accession number JX013656), a novel VIM-type enzyme differing from VIM-1 by one amino acid change (V113I, according to MBL standard numbering scheme) and co-production of SHV-1 (pI = 7.6) and SHV-12 (pI = 8.2) extended-spectrum β-lactamase. We could not identify the origin of these isolates but as both patients had multiple previous hospitalizations (including in other hospitals) and carried the same novel *bla*~VIM~ type, a common nosocomial source seems more plausible than community acquisition.

###### 

MICs of different β-lactam antibiotics for VIM-34-producing wild-type isolates and recombinant strains encoding VIM-34 or VIM-1

  Antibiotic                MIC (mg/L)                   
  ------------------------- ------------ ------- ------- -------
  Amoxicillin/clavulanate   24           2       24      12
  Ticarcillin/clavulanate   \>256        2       \>256   \>256
  Piperacillin/tazobactam   \>256        0.75    6       6
  Cefalotin                 \>256        2       64      32
  Ceftazidime               \>256        0.19    12      8
  Cefotaxime                32           0.125   2       2
  Cefepime                  12           0.016   0.75    0.5
  Cefpirome                 32           0.032   1.5     2
  Cefoxitin                 32           4       12      4
  Aztreonam                 32           0.023   0.023   0.016
  Ertapenem                 0.38^b^      0.006   0.008   0.008
  Imipenem                  1.0^b^       0.125   0.38    0.38
  Meropenem                 0.5^b^       0.016   0.032   0.023

^a^K47 isolate exhibited identical antibiotic susceptibility profiles.

^b^MIC values interpreted as susceptible by both EUCAST and CLSI guidelines, but above the epidemiological cut-off values defined for *K. pneumoniae* (<http://www.eucast.org)>.^[@DKT314C6]^

The *bla*~VIM-34~ from the K47 isolate was cloned in the pBGS18 (kanamycin resistance) plasmid using primers VIM-EcoRI (5′-GG[GAATT]{.ul}CGCAGTCGCCCTAAAACAAAG-3′) and VIM-PstI (5′-AA[CTGCAG]{.ul}CCGCTCCAACGATTTGTTAT-3′) (restriction sites are underlined), and the expression vector (pBGS18/VIM-34) was further introduced into *Escherichia coli* DH5α, as previously reported.^[@DKT314C8]^ MICs of different β-lactams were determined using the Etest (in triplicate) and compared with those corresponding to a *bla*~VIM-1~-carrying clone obtained in the same conditions (Table [1](#DKT314TB1){ref-type="table"}). The VIM-34-producing *E. coli* recombinant yielded β-lactam MIC values similar to those observed in the VIM-1-encoding transformant (with the exception of cefoxitin; Table [1](#DKT314TB1){ref-type="table"}). Because our experiments were performed in an isogenic context and identical standard experimental conditions, we are able to hypothesize that the substitution V113I has a low influence on the MICs of carbapenems, although further studies of enzymatic activity are required to confirm this observation.

The isolates exhibited identical XbaI-PFGE profiles and clonal identification by multilocus sequence typing (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html>) revealed that they belong to the intercontinental ST15 *K. pneumoniae* clone, widely disseminated in different European countries and associated with the spread of extended-spectrum β-lactamases (CTX-M-15; diverse SHV types) and/or MBLs (VIM-1, NDM-1).^[@DKT314C2],[@DKT314C3],[@DKT314C7],[@DKT314C9],[@DKT314C10]^ Conjugation assays performed by broth and/or filter mating methods using *E. coli* HB101 (azide and kanamycin resistant, Lac-, plasmid free) as recipient at 22°C and 37°C (selection of transconjugants in MacConkey agar with 2 mg/L of ceftazidime and 130 mg/L of azide)^[@DKT314C7]^ failed to yield transconjugants either for *bla*~VIM-34~ or *bla*~SHV-12~. The location of *bla* (*bla*~VIM-34~, *bla*~SHV-12~) genes and plasmid characterization were accomplished by S1- and I-CeuI-PFGE, and identification of incompatibility groups.^[@DKT314C7]^ In both isolates, *bla*~VIM-34~, *bla*~SHV-12~ and repHI2 probes hybridized in the same chromosomal band (I-CeuI-PFGE) whereas no signals were observed in the S1 gel, suggesting the acquisition of both *bla* genes by an IncHI2 plasmid and subsequent plasmid (whole or in part) integration. A chromosomal location for *bla* genes, including *bla*~VIM~, has been occasionally observed in different Enterobacteriaceae species.^[@DKT314C1]^

The linkage of *bla*~VIM-34~ to class 1 integrons and Tn*402* derivatives was investigated by PCR (*intI1*, 5′CS-3′CS region, *orf5*, *orf6*, IS*1326*, IS*1353*, IS*6100*) and sequencing.^[@DKT314C4],[@DKT314C11]^*bla*~VIM-34~ was located within an ∼6 kb class 1 integron named In817 by INTEGRALL (<http://integrall.bio.ua.pt/>) (GenBank accession number JX185132), with an original array of gene cassettes comprising *bla*~VIM-34~, *aacA4*′, *aphA15*, *aadA1b* and *catB2* ([Figure S1; available as Supplementary data at *JAC* Online](#sup1){ref-type="supplementary-material"}). The absence of *tni*~402~ sequences and the high similarity detected with In70 and In113, identified in VIM-1-producing *Achromobacter xylosoxidans*, *K. pneumoniae* and *E. coli* isolates, suggests that the In817 integron might have arisen by both recombination and *in vivo* evolution events ([Figure S1; available as Supplementary data at *JAC* Online](#sup1){ref-type="supplementary-material"}).^[@DKT314C4]^

In summary, we present the first report of VIM-34, a VIM-1-like variant embedded in the novel integron type In817 on the chromosome of the intercontinental ST15 *K. pneumoniae* clone, associated with carbapenem susceptibility profiles similar to those observed for VIM-1. This study highlights the risk of further dissemination of the multidrug-resistant ST15 *K. pneumoniae* clone and genetic backgrounds containing metallo-β-lactamase genes in our country, which deserves future monitoring.
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